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Efficacy of eribulin for metastatic 
breast cancer based on localization 
of specific secondary metastases: a 
post hoc analysis
Joyce o’Shaughnessy1 ✉, Javier cortes2, Chris twelves3, Lori J. Goldstein4, Karenza Alexis5, 
Ran Xie5, Carlos Barrios  6 & Takayuki Ueno  7
Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) 
in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral 
disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to 
the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from 
studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; 
OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in 
patients with locally advanced/MBC, irrespective of the location of metastases at baseline. A nominally 
significant difference in OS in favor of patients randomized to eribulin compared with control in patients 
with bone, lymph node, and chest wall/breast/skin metastases at baseline was observed. Additionally, 
a difference in OS was also seen in patients with liver metastases randomized to eribulin versus control 
(median: 13.4 versus 11.3 months, respectively; hazard ratio, 0.84 [95% CI: 0.72, 0.97]). Results of this 
exploratory analysis suggest that eribulin may be efficacious for the treatment of locally advanced/MBC 
for patients with bone, liver, lung, lymph node, and chest wall/breast/skin metastases.
Metastatic breast cancer (MBC) is a heterogenous disease, with metastases commonly located in soft tissue (ie, 
skin, lymph nodes, and the contralateral breast), bone, and visceral organs (ie, lungs, pleura, peritoneum, liver, 
and brain)1. Although treatment for MBC has steadily improved, few agents have been shown to prolong survival 
and MBC remains essentially incurable with a median overall survival (OS) of 2–3 years2,3. Moreover, patients 
with visceral metastases typically have a worse prognosis than patients with nonvisceral metastases2,4–6.
Eribulin is a synthetic analogue of halichondrin B, originally isolated from the marine sponge Halichondria 
okadai7. The antitumor activity of eribulin is driven by a distinct mode of interaction with microtubules, 
in which eribulin inhibits the growth phase but not the shortening phase8–11. In vitro and preclinical studies 
suggest that eribulin may also have nonmitotic mechanisms including vascular remodeling, reversal of the 
epithelial-to-mesenchymal (EMT) transition, and inhibition of cancer cell migration/invasion12–14; some of these 
noncytotoxic effects have also been demonstrated clinically15. In the United States, eribulin is indicated for the 
treatment of patients with MBC who have previously received ≥2 chemotherapeutic regimens for the treatment 
of metastatic disease—prior therapy should have included an anthracycline and a taxane in either the adjuvant 
or metastatic setting. Additionally, approval for eribulin in MBC has been extended to the second-line metastatic 
setting in other geographic areas, including the European Union.
The efficacy of eribulin has been demonstrated in several phase 3 studies (Studies 305, 301, and 304) in 
patients with locally advanced or MBC that had been more heavily pretreated (Studies 305 and 304)16,17 or less 
heavily pretreated (Study 301)18. In the studies included in our analysis (Studies 305 and 301), pretreatment was 
required to include a taxane and an anthracycline16,18. In Study 305 (EMBRACE; NCT00388726), the primary 
1Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA. 2IOB Institute of Oncology, 
Quironsalud Group, Madrid and Barcelona & Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. 3Leeds 
Institute of Medical Research at St James’s and Leeds Teaching Hospitals Trust, Leeds, UK. 4Fox Chase Cancer Center, 
Philadelphia, PA, USA. 5Eisai Inc., Woodcliff Lake, NJ, USA. 6Latin American Cooperative Oncology Group (LACOG), 
Porto Alegre, Brazil. 7Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer 
Research, Tokyo, Japan. ✉e-mail: joyce.oshaughnessy@usoncology.com
open
2Scientific RepoRtS |        (2020) 10:11203  | https://doi.org/10.1038/s41598-020-66980-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
end point was achieved with eribulin significantly improving OS compared with treatment of physicians’ choice 
(TPC; hazard ratio [HR], 0.81 [95% CI: 0.66, 0.99]; P = 0.041)16; an updated OS analysis confirmed this benefit in 
OS for eribulin (13.2 months versus 10.5 months; HR, 0.81 [95% CI: 0.67, 0.96]; P = 0.014)16. Study 301 compared 
eribulin with capecitabine (NCT00337103); eribulin was associated with a nonsignificant increase in OS com-
pared to capecitabine (15.9 months versus 14.5 months, respectively; HR, 0.88 [95% CI: 0.77, 1.00]; P = 0.056)18. 
In both studies, the toxicity of eribulin was manageable and comparable to that of other chemotherapeutic agents 
used in this setting16,18.
Although eribulin is widely used in patients with previously treated MBC, its efficacy according to meta-
static organ sites has not been well characterized. However, in one earlier subgroup analysis of Studies 305 and 
301 combined19, eribulin improved OS compared with TPC/capecitabine in patients with visceral (median OS, 
14.3 versus 12.2 months; HR 0.89; P = 0.037) and nonvisceral (median OS, 18.8 versus 16.6 months; HR 0.72; 
P = 0.045) disease; moreover, greater benefit was seen with eribulin compared with TPC/capecitabine in patients 
with >2 involved metastatic organ sites (median OS, 13.1 versus 10.5 months; HR 0.77; P < 0.001)19. In this cur-
rent post hoc pooled exploratory analysis of Studies 30516 and 30118 we assess OS, progression-free survival (PFS), 
and objective response rate (ORR) according to organ sites of metastases at baseline for patients randomized to 
receive eribulin versus TPC/capecitabine. Additionally, we present the percentage change in the sum of the diam-
eters of target lesions from baseline to postbaseline nadir according to sites of metastases (ie, waterfall plots) and 
OS and PFS according to metastatic site and estrogen-receptor (ER) status.
Methods
Patients. Patient eligibility criteria for Study 30516 and Study 30118 have been published. Briefly, eligible 
patients were women ≥18 years of age with histologically or cytologically confirmed breast cancer, an Eastern 
Cooperative Oncology Group performance status of 0–2, and adequate bone marrow, liver, and renal function. In 
Study 305, patients were previously treated with 2–5 chemotherapy regimens (of which ≥2 were for locally recur-
rent breast cancer or MBC)16, and in Study 301, patients were previously treated with ≤3 chemotherapy regimens 
(of which ≤2 were for advanced and/or metastatic disease)18.
The source Studies 305 and 301 were conducted in accordance with the World Medical Association 
Declaration of Helsinki, ethical standards of the responsible committee on human experimentation (institu-
tional and national), and guidelines of the International Conference for Harmonization/Good Clinical Practice. 
Informed consent was obtained from all individual participants included in the studies and both studies were 
approved by ethics committees (Study 305: The New York Presbyterian Hospital-Weil Medical College of Cornell 
University Committee on Human Rights in Research [for the lead investigator in the United States]; Study 301: 
Committee for the Protection of Human Subjects [for the lead investigator in the United States]).
Study design and treatment. Studies 305 and 301 were phase 3, multicenter, open-label, randomized tri-
als that compared the efficacy of eribulin with TPC (Study 305) or capecitabine (Study 301) in women with locally 
advanced/MBC16,18. In Study 305, patients were randomly assigned (2:1) to either eribulin mesylate (1.4 mg/m2 
[equivalent to eribulin 1.23 mg/m2 when expressed as a free base]; administered intravenously over 2–5 minutes 
on days 1 and 8 of a 21-day cycle) or TPC (any single-agent chemotherapy, or hormonal or biological therapy 
approved for the treatment of cancer and administered according to local practice; radiotherapy; or symptomatic 
treatment alone). In Study 301, patients were randomly assigned (1:1) to either eribulin mesylate (1.4 mg/m2; 
intravenously over 2–5 minutes on days 1 and 8 of a 21-day cycle) or capecitabine (1.25 g/m2; orally twice daily on 
days 1–14 of a 21-day cycle). Treatment in both studies continued until disease progression, unacceptable toxicity, 
or patient/investigator request to discontinue.
Study end points. The primary end point of Study 305 was OS; secondary end points included PFS, ORR, 
and duration of response16. Tumor response was assessed with Response Evaluation Criteria In Solid Tumors 
(RECIST) version 1.020 and all secondary end points were carried out by independent masked review of tumor 
assessments. Additionally, sensitivity analyses were completed based on investigator review.
In Study 301, OS and PFS were co-primary end points18. Secondary end points included ORR, duration 
of response, safety, quality of life, and population pharmacokinetic/pharmacodynamic relationships. Tumor 
response was assessed with RECIST version 1.020 by independent radiology review (primary analysis) and inves-
tigator review (secondary analysis).
Findings for the primary and secondary end points of both studies have been published16,18.
Post Hoc subgroup analyses. Subgroup analyses of data pooled from Studies 305 and 301 were conducted 
to compare the efficacy of eribulin with TPC/capecitabine according to the organ sites of metastases. Patients were 
divided into subgroups according to metastatic sites. The following sites were observed in >5% of all patients at 
baseline and were included in this analysis: bone, liver, lymph node, chest wall/breast/skin, or lung. Target and 
nontarget lesions were included. Of note, patients with metastases in more than 1 organ site were included in the 
analyses for multiple subgroups.
Analyses included OS, PFS, ORR, and percentage change in the sum of diameters of target lesions from baseline 
to postbaseline nadir. Moreover, analyses of OS and PFS were conducted according to ER status in each subgroup.
Statistical methods. Analyses were conducted with pooled data and included patients in the 
intention-to-treat population (all patients randomly assigned to treatment groups). To determine median OS 
and PFS (including OS and PFS by ER status), estimates of survival were adjusted by study using methodology 
previously outlined in a separate pooled analysis of Studies 305 and 30119.
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For all OS and PFS analyses, HR values and 2-sided 95% CIs were computed using Cox models with treatment 
as a covariate and stratified by study, region, prior capecitabine use, and HER2/neu status. Because these post hoc 
analyses involved multiple comparisons, all P values should be considered nominal and should not be used to 
directly determine statistical significance; nominal P values were based on log-rank tests and stratified as noted 
above. For ORR, odds ratios (95% CIs) of treatments were computed using Cochran-Mantel-Haenszel test, strat-
ified by study. Tumor responses were based on investigator review per RESIST version 1.0.
Results
Patients. Patient dispositions for Study 305 and Study 301 have been reported elsewhere16,18. Overall, 1864 patients 
(Study 305, n = 762; Study 301, n = 1102) were included in this pooled post hoc subgroup analysis. Of these patients, 
1062 were assigned to receive eribulin (Study 305, n = 508; Study 301, n = 554), 254 to receive TPC (Study 305), and 
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Figure 1. Summary of overall survival (a) and progression-free survival (b) in patients with locally advanced/
MBC, by site of lesions at baseline (pooled population). (a) Patients randomized to eribulin had a nominally 
significant difference in overall survival compared with control in the overall pooled population. Patients 
with bone, liver, lymph node and chest wall/breast/skin metastases had a nominally significant difference in 
overall survival with eribulin compared with TPC/capecitabine. (b) Overall, patients treated with eribulin had 
a nominally significant difference compared with control in progression-free survival. Assessment by baseline 
lesion location, revealed only patients with baseline bone metastases randomized to eribulin had a nominally 
significant difference in progression-free survival compared with TPC/capecitabine. Control includes TPC and 
capecitabine; HR values and 2-sided 95% CIs were computed using Cox models with treatment as a covariate 
and stratified by study, region, prior capecitabine use, and HER2/neu status; nominal P values were based 
on log-rank tests and stratified as noted above. Medians were based on survival curves adjusted by study. CI, 
confidence interval; HR, hazard ratio; MBC, metastatic breast cancer; TPC, treatment of physician’s choice.
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548 to receive capecitabine (Study 301)16,18. The mean dose intensity of eribulin in Study 305 was 0.78 mg/m2/week 
(standard deviation, 0.166); in Study 301, the mean dose intensity of eribulin was 0.81 mg/m2/week (standard devi-
ation, 0.14), and the mean dose intensity of capecitabine was 9983.86 mg/m2/week (standard deviation, 1814.27).
In the pooled analysis, the median duration of treatment with eribulin was 119 days (range: 21–1372 days) and 
the median duration of treatment with TPC/capecitabine was 93 days (range: 1–1442 days).
Overall, the most common metastatic sites were in bone (eribulin, 57.0%; TPC/capecitabine, 58.1%) and liver 
(eribulin, 51.1%; TPC/capecitabine, 53.6%). Additional details regarding patient demographics and baseline 
characteristics have been published previously16,18.
Efficacy. Subgroup analyses of survival by metastatic site. In the overall pooled analysis, patients randomized 
to receive eribulin had a nominally significant difference in OS compared with patients randomized to receive 
TPC/capecitabine (median: 14.9 versus 12.9 months; HR, 0.86 [95% CI: 0.77, 0.96]) (Fig. 1a). In addition, OS 
for the eribulin group differed from the TPC/capecitabine group across all metastatic sites (Fig. 1a). Of note, 
patients with liver metastases who were randomized to receive eribulin had a nominally significant difference in 
OS compared with patients who were randomized to receive TPC/capecitabine (median:13.4 versus 11.3 months; 
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Figure 2. Estimated overall survival in patients with locally advanced/MBC with liver (a) and lung (b) 
metastases at baseline (pooled population). (a) Patients with baseline liver metastases randomized to eribulin 
had a nominally significant difference in overall survival compared with patients randomized to TPC/
capecitabine. (b) Patients with baseline lung metastases randomized to eribulin had no significant difference 
in overall survival compared to control. Control includes TPC and capecitabine; HR values and 2-sided 95% 
CIs were computed using Cox models with treatment as a covariate and stratified by study, region, prior 
capecitabine use, and HER2/neu status; nominal P values were based on log-rank tests and stratified as noted 
above. Medians were based on survival curves adjusted by study. CI, confidence interval; HR, hazard ratio; 
MBC, metastatic breast cancer; TPC, treatment of physician’s choice.
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HR, 0.84 [95% CI: 0.72, 0.97]) (Fig. 2); a nominally significant difference in OS was also observed in patients with 
metastases in bone (median: 14.6 versus 12.5 months; HR, 0.76 [95% CI: 0.66, 0.88]), lymph nodes (median: 14.4 
versus 11.8 months; HR, 0.82 [95% CI: 0.70, 0.97]), and chest wall/breast/skin (median: 15.5 versus 11.2 months; 
HR, 0.81 [95% CI: 0.66, 0.98]) (Fig. 1a).
 The median overall PFS was 4.0 months for patients randomized to eribulin versus 3.4 months for patients 
randomized to TPC/capecitabine; the HR for progression-free survival was 0.89 (95% CI: 0.80, 0.99) (Fig. 1b). In 
analyses of specific subgroups, only patients with bone metastases randomized to receive eribulin had a nominally 
significant difference in PFS compared with patients randomized to receive TPC/capecitabine (median: 4.1 versus 
3.1 months; HR, 0.77 [95% CI: 0.67, 0.89]) (Fig. 1b). PFS results were similar in the eribulin group and TPC/capecit-
abine group for patients with other sites of metastases, including patients with metastases in the liver (median: 3.7 
versus 2.8 months; HR, 0.87 [95% CI: 0.75, 1.02]) (Figs. 1b and 3a), lung (median: 3.7 versus 3.0 months; HR, 0.95 
[95% CI: 0.81, 1.11]) (Figs. 1b and 3b), lymph nodes (median: 3.8 versus 3.2 months; HR, 0.96 [95% CI: 0.82, 1.12] 
(Fig. 1b), and chest wall/breast/skin (median: 3.6 versus 2.9; HR, 0.86 [95% CI: 0.71, 1.05]) (Fig. 1b).
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Figure 3. Estimated progression-free survival in patients with locally advanced/MBC with liver (a) and lung 
(b) metastases at baseline (pooled population). (a) Progression-free survival was similar in patients with 
baseline liver metastases regardless of treatment. (b) Similar results were seen in patients with baseline lung 
metastases. Control includes TPC and capecitabine; HR values and 2-sided 95% CIs were computed using 
Cox models with treatment as a covariate and stratified by study, region, prior capecitabine use, and HER2/
neu status; nominal P values were based on log-rank tests and stratified as noted above. Medians were based 
on survival curves adjusted by study. CI, confidence interval; HR, hazard ratio; MBC, metastatic breast cancer; 
TPC, treatment of physician’s choice.
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The results of these pooled analyses are generally consistent with the results of the analyses of OS and PFS by 
metastatic organ site at baseline in the individual Studies 305 and 301 (Online Resource Supplemental Figs. 1 and 2).
Subgroup analyses of survival by metastatic site and ER status. In patients with ER-positive disease, nominally 
significant differences in OS were observed with the eribulin group compared with the TPC/capecitabine group 
in patients with metastases to the bone (median: 14.7 versus 13.5 months, respectively; HR, 0.79 [95% CI: 0.66, 
0.96]) or liver (median: 14.4 versus 12.5 months, respectively; HR, 0.81 [95% CI: 0.66, 0.99]) (Fig. 4a); nominally 
significant differences in PFS were also seen with metastases to the bone (median: 4.2 versus 3.4 months, respec-
tively; HR, 0.76 [95% CI: 0.64, 0.91]) or liver (median: 4.1 versus 2.8 months, respectively; HR, 0.79 [95% CI: 0.65, 
0.96]) (Fig. 4b).
In patients with ER-negative disease, the eribulin group had nominally significant differences in OS com-
pared with the TPC/capecitabine group in patients with metastases to the bone (median: 13.8 versus 8.6 months, 
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Figure 4. Overall survival (a) and progression-free survival (b) in estrogen-receptor–positive patients with 
locally advanced/MBC, by site of lesions at baseline (pooled population). (a) Overall survival was nominally 
significantly different in estrogen-receptor-positive patients with bone or liver metastases at baseline randomized 
to eribulin compared with TPC/capecitabine. (b) In the overall population, progression-free survival was 
nominally significantly different in estrogen-receptor-positive patients randomized to eribulin compared with 
control. Patients with bone or liver metastases at baseline randomized to eribulin had a nominally significant 
difference in progression-free survival compared with TPC/capecitabine. Control includes TPC and capecitabine. 
HR values and 2-sided 95% CIs were computed using Cox models with treatment as a covariate and stratified by 
study, region, prior capecitabine use, and HER2/neu status; nominal P values were based on log-rank tests and 
stratified as noted above. Medians were based on survival curves adjusted by study. CI, confidence interval; HR, 
hazard ratio; MBC, metastatic breast cancer; TPC, treatment of physician’s choice.
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respectively; HR, 0.62 [95% CI: 0.47, 0.83]), lung (median: 11.3 versus 8.7 months, respectively; HR, 0.77 [95% 
CI: 0.60, 0.99]), lymph nodes (median: 11.6 versus 8.8 months, respectively; HR, 0.69 [95% CI: 0.55, 0.88]), or 
chest wall/breast/skin (median: 12.2 versus 8.7 months, respectively; HR, 0.70 [95% CI: 0.52, 0.94]); a numerical 
difference in OS was observed in patients with liver metastases (median: 10.8 versus 8.5 months; HR, 0.75 [95% 
CI: 0.57, 1.00]) (Fig. 5a). Only patients with ER-negative disease and bone metastases had a nominally significant 
difference in PFS (median: 3.5 versus 2.8 months; HR, 0.72 [95% CI: 0.54, 0.96]) with randomization to eribulin 
versus TPC/capecitabine (Fig. 5b).
Tumor response according to sites of metastases at baseline. ORR was similar for patients randomized to eribulin 
(14.3% [95% CI: 12.3, 16.6]) and TPC/capecitabine (15.6% [95% CI: 13.1, 18.3] in the overall pooled population 
(Fig. 6). Individual analyses of ORR by site of metastases at baseline in Studies 305 and 301 are included in Online 
Resource Supplemental Figs. 3 and 4. A nominally significant difference in ORR between the treatment groups 
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Figure 5. Overall survival (a) and progression-free survival (b) in estrogen-receptor–negative patients with 
locally advanced/MBC, by site of lesions at baseline (pooled population). (a) Overall survival was nominally 
significantly different in estrogen-receptor-negative patients in the overall population, and in patients with 
bone, lung, lymph node or chest wall/breast/skin metastases at baseline randomized to eribulin compared with 
TPC/capecitabine. (b) Progression-free survival was nominally significantly different only in estrogen-receptor-
negative patients with bone metastases at baseline randomized to eribulin compared with TPC/capecitabine. 
Control includes TPC and capecitabine; HR values and 2-sided 95% CIs were computed using Cox models with 
treatment as a covariate and stratified by study, region, prior capecitabine use, and HER2/neu status; nominal 
P values were based on log-rank tests and stratified as noted above. Medians were based on survival curves 
adjusted by study. CI, confidence interval; HR, hazard ratio; MBC, metastatic breast cancer; TPC, treatment of 
physician’s choice.
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Figure 6. Summary of tumor response as assessed by investigators per RECIST version 1.0, by site of lesions at 
baseline (pooled population). The overall response rates were similar across the pooled population regardless of 
location of metastases at baseline. Control includes TPC and capecitabine; odds ratio (95% CI) was calculated 
using Cochran-Mantel-Haenszel test, stratified by study. CI, confidence interval; RECIST, Response Evaluation 
Criteria In Solid Tumors; TPC, treatment of physician’s choice.
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Figure 7. Percentage change in sum of diameters of target lesions from baseline to postbaseline nadir, by 
metastatic site at baseline in patients randomized to receive eribulin (a) or control (b) (pooled population). 
Patients with liver, lung, lymph node or chest wall/breast/skin metastases showed decreased tumor sizes 
when treated with (a) eribulin or (b) TPC/capecitabine. n is the number of patients with both baseline and 
postbaseline measurements of target lesions.
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was observed for the overall population, bone metastases, and liver metastases in Study 305 (Online Resource 
Supplemental Fig. 3). For Study 301, none of the observed differences in ORR were nominally significant (Online 
Resource Supplemental Fig. 4).
Analyses of percentage change in sum of diameters of target lesions from baseline to postbaseline nadir by metastatic site. 
Among patients with both baseline and postbaseline measurements of target lesions, 63% (544/857) randomized 
to receive eribulin and 63% (403/638) randomized to receive TPC/capecitabine experienced a reduction in tumor 
size in postbaseline nadir imaging studies (ie, percentage change in the sum of the diameters of the target lesions 
from baseline to postbaseline nadir imaging studies showed a reduction in tumor size). Of patients with liver 
metastases randomized to receive eribulin or TPC/capecitabine, 66% (n = 325/492) and 63% (n = 231/367) 
respectively, had reductions in tumor size on postbaseline nadir imaging studies (Fig. 7). Similar results for 
eribulin versus TPC/capecitabine were seen for patients with lung metastases (63% [n = 252/401] versus 61% 
[n = 190/309]), lymph node metastases (68% [n = 294/431] versus 65% [220/339]), and chest wall/breast/skin 
metastases (66% [n = 173/264] versus 62% [n = 131/212]) (Fig. 7).
Discussion
The efficacy of eribulin in locally advanced/MBC has been previously established in Studies 305 and 301, which 
demonstrated a statistically significant improvement in OS compared with TPC (Study 305: P = 0.041)16, and 
similar OS compared with capecitabine (Study 301: P = 0.056)18. The results from this post hoc exploratory 
pooled analysis are largely consistent with these findings. Our current analyses provide insights into the efficacy 
of eribulin with regard to the organ sites of metastases at baseline. Such insights are of potential relevance because 
a patient’s prognosis is dependent on the location of metastases at baseline. Specifically, patients with visceral 
disease (eg, metastases in the lung, liver, brain) are known to have reduced survival duration4, and among patients 
with visceral disease, metastases to the liver (median OS, 13 months) or brain (median OS, 7 months) generally 
portend the worst prognosis21.
The pooled analysis presented here suggests that eribulin may be an effective treatment option in patients 
with locally advanced/MBC, irrespective of their organ sites of metastatic disease at baseline (ie, bone, liver, lung, 
lymph nodes, and chest wall/breast/skin). In this analysis, nominal differences in OS (P = 0.02) were observed in 
favor of eribulin versus TPC/capecitabine in patients with liver metastases at baseline. ORRs were similar with 
eribulin (17.1%) and TPC/capecitabine (16.5%) in this population. Given the typically poor prognosis of patients 
with chemotherapy-pretreated bone, liver, lung, lymph nodes, and chest wall/breast/skin metastases, the efficacy 
of eribulin in these patients is noteworthy. Moreover, the ability of eribulin to reduce target lesion tumor size may 
be clinically significant in reducing metastases-associated symptoms and organ dysfunction.
The consistent efficacy of eribulin across metastatic sites is likely the result of its mechanism of action (ie, its 
unique interaction with microtubules)8–11. Eribulin’s efficacy against difficult-to-treat liver metastases, in par-
ticular, may be the result of a multifaceted interplay between eribulin’s mechanism of action and the complex 
microenvironment of the liver. Specifically, the potential for eribulin to reverse EMT and inhibit cancer cell 
migration/invasion may provide a mechanistic advantage for eribulin in the treatment of liver metastases, given 
that liver sinusoidal endothelial cells have been shown to induce EMT in colorectal cancer cells12–14,22.
Of interest, the absolute prolonged median OS time difference with eribulin compared with control was 2.0 
months (eribulin, 14.9 months; control, 12.9 months), whereas the absolute prolonged time of median PFS dif-
ference with eribulin compared to control was 0.6 months (eribulin, 4.0 months; control, 3.4 months). Previous 
studies with eribulin have suggested that the discordance between OS and PFS improvement may be partly due 
to eribulin’s ability to remodel the tumor microenvironment and vasculature; such remodeling may improve 
the antitumor activity of eribulin, as well as positively impact the efficacy of subsequent anticancer therapies, 
resulting in improved OS13,23. Additionally, a previous study by Twelves et al.24 indicated that the development 
of new metastasis is a risk factor for shorter OS. As both growth of existing metastasis and development of new 
metastasis are considered “progression” in terms of PFS, whereas the more aggressive form of progression (ie, 
development of new metastasis) is considered a risk factor for shorter OS, the difference between these forms 
of progressive disease may not be captured by the PFS end point but instead may be reflected in the OS end 
point. Moreover, in support of this theory, Twelves et al. showed that new-metastasis-free survival was longer 
in the eribulin arm than in the comparator arm in EMBRACE, which could account for the improved OS seen 
with eribulin treatment24. This may provide a rationale for the more prolonged OS, but not PFS, observed in 
eribulin-treated patients in the current analysis.
This analysis is limited by the relatively small number of patients in each subgroup, its post hoc nature, and 
the multiple testing comparisons; as such, P values are considered nominal. Despite these limitations, the results 
of this post hoc analysis are consistent with previous findings of eribulin’s efficacy in locally advanced/MBC16,18, 
and suggest that eribulin can be an effective treatment option in patients with bone, liver, lung, lymph node, and 
chest wall/breast/skin metastases.
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